The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

Clearside is now looking at a Phase III trial as it plans to meet with the FDA early next year to discuss the new Phase IIb ...

Ocular Therapeutix's Elutyx drug delivery platform offers sustained long-term effects. See why OCUL stock is a Buy.

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory ...

ANX007 Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Photoreceptor Preservation in the Fovea ...

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Sector ...

We now introduce an algorithm called Root Causal Strength using Perturbations (RCSP) that discovers the surrogate ancestors of each variable using Perturb-seq and then computes the RCS of each ...

The Exascale Era began in spring 2022 when the Top500 list certified that the HPE-AMD Frontier supercomputer at Oak Ridge ...

Dr. Eric Guglielmo, above, recently joined Dr. Frank Venzara III and Dr. Timothy Tweito in the busy Florida Retina Specialists practice with offices in Merritt Island and Viera.

Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. PMC-403 is being explored in broader therapeutic ...

Fish oil can offer several health benefits for men, including increasing fertility and improving heart health. However, ...